Literature DB >> 1638534

Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines.

Y Yaginuma1, H Westphal.   

Abstract

In an effort to analyze molecular mechanisms of human ovarian carcinogenesis, we studied the structure and expression of the p53 gene in different cell lines established from human ovarian carcinomas. In all six lines (PA-1, Caov-3 and -4, OVCAR-3, SK-OV-3, and Kuramochi), p53 abnormalities were detected. In the SK-OV-3 cell line, Southern analysis suggested the presence of sequence deletions/rearrangements in at least one allele of the p53 gene, and transcripts were not detectable by either Northern or polymerase chain reaction analysis. Sequence analysis of the entire coding region of the p53 gene revealed point mutations resulting in codon changes of a highly conserved region of the protein in four cell lines, Caov-3 and -4, OVCAR-3, and Kuramochi. In the Caov-3 cell line, the point mutation resulted in chain termination at codon 136. Quantitation of p53 protein by immunoprecipitation analysis revealed a 6-fold higher than control cell level in PA-1. By contrast, p53 protein was not detectable in lines Caov-3 and SK-OV-3. We conclude that altered levels of p53 gene expression and/or mutant forms of the p53 gene product are associated with all human ovarian cancer cells tested.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1638534

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  74 in total

1.  p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication.

Authors:  J N Harada; A J Berk
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Flow Cytometric Analyses of p53-Mediated Cell Cycle Arrest and Apoptosis in Cancer Cells.

Authors:  Nour N Al Zouabi; Cai M Roberts; Z Ping Lin; Elena S Ratner
Journal:  Methods Mol Biol       Date:  2021

3.  Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers.

Authors:  Chad J Creighton; Michael D Fountain; Zhifeng Yu; Ankur K Nagaraja; Huifeng Zhu; Mahjabeen Khan; Emuejevoke Olokpa; Azam Zariff; Preethi H Gunaratne; Martin M Matzuk; Matthew L Anderson
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

4.  Innate immune agonist, dsRNA, induces apoptosis in ovarian cancer cells and enhances the potency of cytotoxic chemotherapeutics.

Authors:  Danielle N Van; Charlotte F Roberts; James D Marion; Sandrine Lépine; Kuzhuvelil B Harikumar; Jessica Schreiter; Catherine I Dumur; Xianjun Fang; Sarah Spiegel; Jessica K Bell
Journal:  FASEB J       Date:  2012-04-24       Impact factor: 5.191

5.  Synergistic growth inhibition by combination of adenovirus mediated p53 transfer and cisplatin in ovarian cancer cell lines.

Authors:  Sang Young Ryu; Kidong Kim; Woo Sik Lee; Hee Chung Kwon; Kee Ho Lee; Chang Min Kim; Soon-Beom Kang
Journal:  J Gynecol Oncol       Date:  2009-03-31       Impact factor: 4.401

6.  Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescence.

Authors:  Benjamin G Bitler; Jasmine P Nicodemus; Hua Li; Qi Cai; Hong Wu; Xiang Hua; Tianyu Li; Michael J Birrer; Andrew K Godwin; Paul Cairns; Rugang Zhang
Journal:  Cancer Res       Date:  2011-08-04       Impact factor: 12.701

7.  Identification of ribonucleotide reductase M2 as a potential target for pro-senescence therapy in epithelial ovarian cancer.

Authors:  Katherine M Aird; Hua Li; Frances Xin; Panagiotis A Konstantinopoulos; Rugang Zhang
Journal:  Cell Cycle       Date:  2013-10-29       Impact factor: 4.534

8.  Cytotoxic susceptibility and defective MHC class I expression do not correlate with mutation of p53 in human carcinomas.

Authors:  Z Végh; P Wang; F Vánky; C Hising; K Sjöwall; B Larsson; E Klein
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

9.  p150(Sal2) is a p53-independent regulator of p21(WAF1/CIP).

Authors:  Dawei Li; Yu Tian; Yupo Ma; Thomas Benjamin
Journal:  Mol Cell Biol       Date:  2004-05       Impact factor: 4.272

10.  c-Jun NH2-terminal kinase activating kinase 1/mitogen-activated protein kinase kinase 4-mediated inhibition of SKOV3ip.1 ovarian cancer metastasis involves growth arrest and p21 up-regulation.

Authors:  Tamara Lotan; Jonathan Hickson; Jeffrey Souris; Dezheng Huo; Jennifer Taylor; Terry Li; Kristen Otto; Seiko Diane Yamada; Kay Macleod; Carrie W Rinker-Schaeffer
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.